MedTrace Logo

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

NCT03054896 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2025-08-14

No results posted yet for this study

Summary

This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome.

The drugs involved in this study are:

* Venetoclax
* R-EPOCH:

* Rituximab
* Etoposide
* Prednisone
* Vincristine Sulfate (Oncovin)
* Cyclophosphamide
* Doxorubicin Hydrochloride (Hydroxydaunomycin)
* R-CHOP:

* Rituximab
* Cyclophosphamide Vincristine
* Doxorubicin Hydrochloride (Hydroxydaunomycin)
* Sulfate (Oncovin)
* Prednisone

Conditions

  • Richter Syndrome

Interventions

DRUG

Venetoclax

Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor

OTHER

DA-EPOCH-R

Intensive chemotherapy regiment

OTHER

R-CHOP

Intensive chemotherapy regiment

Sponsors & Collaborators

Principal Investigators

  • Matthew S. Davids, MD, MMSc · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-08
Primary Completion
2024-12-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03054896 on ClinicalTrials.gov